Page 144 - CW E-Magazine (25-3-2025)

Top Stories Pharmaceuticals

ENHANCED CUSTOMER SUPPORT PHARMA INDUSTRY SERVICES

Mitsui Chemicals opens coating technical centre Shilpa Medicare expands CDMO offerings with new

in Gurugram full-service hybrid model

Japan’s Mitsui Chemicals Inc. has Karnataka-based Shilpa Medicare
announced that its subsidiary Mitsui has launched its new full service
Chemicals India Pvt. Ltd. has opened ‘hybrid’ CDMO (Contract Development
a Coating Technical Centre (CTC) in and Manufacturing Organisation),
Gurugram, Haryana. expanding capabilities to serve both
small and large molecules customers as
The centre is expected to improve well as peptides.
technical support capabilities in the
company’s coatings and engineering The announcement was made at the
materials business. DCAT 2025, held in New York, USA
ing machines capable of handling all customers on getting the most out of from March 17-20. This networking
Against the backdrop of mounting kinds of coating methods – including Mitsui Chemicals’ products,” the com- platform for industry leaders from the
concern about environmental problems gravure, reverse gravure and air knife – pany stated. pharmaceutical and biotechnology in-
and the tightening of government regula- along with analysers. “This will dustries is hosted annually by the Drug,
tions, India is seeing growing demand for allow customers’ issues to be quickly By continuing to enhance the Chemical & Associated Technologies
sustainable packaging, the company said resolved in India rather than having to CTC’s capabilities, develop new pro- Association (DCAT).
in a press note. “The CTC has been esta- send products to Japan for testing and ducts and establish research centres,
blished to serve as a base for providing evaluation, as had been the case pre- Mitsui Chemicals is planning to fur- In addition to offering compre-
technical support, with plans to swiftly viously. In addition, the CTC will help ther bolster its presence in India. This hensive discovery, clinical, and com-
and precisely meet the needs of custo- support customers in developing pro- is also expected to boost its ability to mercial outsourcing services, Shilpa’s
mers in the Indian market,” it added. ducts by undertaking R&D focused on provide technical support to neighbour- ‘hybrid CDMO model’ also includes
the latest coating technologies, as well ing regions such as the Middle East commercially ready ‘off-the-shelf’ bring commercial products to market. mulation technologies such as liquid-
The facility is equipped with coat- as by providing technical guidance to and Africa. novel formulations for exclusive B2B On the one hand, they can leverage our lyophilisation, nano liposomes, and
licensing. This dual approach enables development teams, cutting-edge tech- microfl uidisation.
ACQUISITION
pharmaceutical companies to leverage nologies, and world-class facilities in a
Blackstone offers $1.2-bn for Akzo Nobel India’s paint Shilpa’s expertise in oncology without traditional CDMO partnership. On the Development and commercial deal
the direct risks and lengthy timelines other, we have a pipeline of fully deve- with Swiss fi rm
business associated with development, the loped products that are available for In another development, Shilpa
company said in a press note. exclusive licensing, eliminating deve- Medicare said its fully owned subsi-
Blackstone, world’s biggest alterna- and International Research Centre from lopment risks for our partners. However, diary, Shilpa Biologicals, has inked an
tive asset manager, has reportedly made AkzoNobel India. Apart from Black- The CDMO currently has multiple we remain strictly a B2B-only company, exclusive co-development and commer-
an acquisition offer for decorative stone, Pidilite and JSW Group are also assets in its pipeline and three late- ensuring we never compete with our cialisation partnership with Swiss
paints business of AkzoNobel India, a in the fray for the pain business, the stage products available for licencing. clients.” biotech fi rm, mAbTree Biologics AG,
Business Standard report said. Accord- report added. In case AkzoNobel NV Through this model, pharma companies for the latter’s its novel biologic asset
ing to the report, it is a non-binding accepts Blackstone’s offer, the asset can expedite their market entry by Wide-ranging capabilities (a checkpoint inhibitor) for immuno-
offer with the paint business being manager will commence all the neces- licensing fully developed products Shilpa Medicare operates fi ve R&D oncological applications.
valued at somewhere around $1.2-bn. sary reports and make the fi nal offer. while still benefi ting from Shilpa’s deve- centres and six manufacturing facilities.
lopment and manufacturing capabilities. These include two dedicated drug sub- Under the terms of the deal, Shilpa
The development comes days after In the last analyst call, AkzoNobel stance plants, three drug product plants, Biologicals will support both develop-
Blackstone revealed its strategy to go NV management had expressed interest Commenting on the business re- and advanced platform technologies ment – including clinical studies – as
big in terms of investments in India. in selling its paint business by the end alignment and hybrid model, Mr. Vishnu- for high-potency compounds (OEB 5), well as long-term commercial supply
The fi rm is eyeing over $100-bn invest- AkzoNobel NV currently owns of this year. The company is likely kant Bhutada, Managing Director of ADCs, peptides, and polymers. The with GMP manufacturing. Addition-
ments in the country with focus on 74.76 per cent in the Indian entity, and to keep 10 percent stake in the paint Shilpa Medicare, said, “Our goal is to total API reactor volume exceeds 800- ally, Shilpa will provide mAbTree
sectors such as healthcare, consumer the Dutch parent recently said it is ac- business after the sale, the management offer pharmaceutical and biotech cus- KL, with two separate commercial drug access to India and several global markets
retail among other things. quiring the powder coating operations had said. tomers multiple fl exible pathways to product lines featuring advanced for- through its partner network.

144 Chemical Weekly March 25, 2025 Chemical Weekly March 25, 2025 145

Contents Index to Advertisers Index to Products Advertised